We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification

By LabMedica International staff writers
Posted on 10 Sep 2025

High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical tumor in the World Health Organization (WHO) classification, yet misclassification may still occur. A new clinicopathologic study shows that most of these tumors originate from the upper genital tract, supporting the exclusion of primary cervical serous carcinoma.

Researchers from Yale School of Medicine (New Haven, CT, USA) and University of Louisville (Louisville, KY, USA) analyzed cases from 2013 to 2023 that were originally diagnosed as “serous carcinoma” or “high-grade serous carcinoma” in cervical or endocervical biopsies. Clinical records, radiologic findings, and follow-up information were reviewed, while histologic and immunohistochemical profiles were reassessed. Targeted next-generation sequencing was also performed on a subset of cases to determine molecular features.


Image: High-grade serous carcinomas identified in cervical biopsies (Photo courtesy of Tong Sun)
Image: High-grade serous carcinomas identified in cervical biopsies (Photo courtesy of Tong Sun)

The study included 59 cases, with 96% of tumors shown to originate from the endometrium or tubo-ovarian region. Only one case was confirmed as a true primary cervical carcinoma. All tumors demonstrated aberrant p53 expression and diffuse p16 positivity, while WT-1 expression and hormone receptor status varied depending on origin. Molecular analysis confirmed p53 mutations typical of uterine serous carcinoma.

These findings, published in the Journal of Clinical and Translational Pathology, demonstrate that high-grade serous carcinoma identified in cervical biopsies is overwhelmingly secondary to tumors from the upper genital tract. Morphologic overlap with HPV-associated adenocarcinoma highlights the importance of precise histologic and molecular characterization. The study supports the WHO’s decision to exclude primary cervical serous carcinoma and emphasizes accurate diagnosis to ensure appropriate patient management and treatment planning.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
HPV Test
Allplex HPV28 Detection

Latest Pathology News

Study Highlights Biomarker Testing Delays in Lung Cancer Care
10 Sep 2025  |   Pathology

Stain-Free Imaging Platform Matches Standard Cancer Pathology
10 Sep 2025  |   Pathology

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
10 Sep 2025  |   Pathology



ADLM